Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.

H Self, Wesley; W Tenforde, Mark; P Rhoads, Jillian; Gaglani, Manjusha; A Ginde, Adit; J Douin, David; M Olson, Samantha; Keipp Talbot, H; D Casey, Jonathan; M Mohr, Nicholas; Zepeski, Anne; McNeal, Tresa; Ghamande, Shekhar; W Gibbs, Kevin; Clark Files, D; N Hager, David; Shehu, Arber; E Prekker, Matthew; L Erickson, Heidi; N Gong, Michelle; Mohamed, Amira; J Henning, Daniel; S Steingrub, Jay; D Peltan, Ithan; M Brown, Samuel; T Martin, Emily; S Monto, Arnold; Khan, Akram; L Hough, Catherine; W Busse, Laurence; C Ten Lohuis, Caitlin; Duggal, Abhijit; G Wilson, Jennifer; June Gordon, Alexandra; Qadir, Nida; Y Chang, Steven; Mallow, Christopher; Rivas, Carolina; M Babcock, Hilary; H Kwon, Jennie; C Exline, Matthew; Halasa, Natasha; D Chappell, James; S Lauring, Adam; G Grijalva, Carlos; W Rice, Todd; D Jones, Ian; B Stubblefield, William; Baughman, Adrienne; N Womack, Kelsey

doi:10.15585/mmwr.mm7038e1

Public

Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.

Published in MMWR. Morbidity and mortality weekly report • Sep 24, 2021

NobleIDark:/48914/w1/20260526/3693FCA6Record on NobleID

Authors:

Wesley H Self

,

Mark W Tenforde

,

Jillian P Rhoads

Abstract

Three COVID-19 vaccines are authorized or approved for use among adults in the United States (1,2). Two 2-dose mRNA vaccines, mRNA-1273 from Moderna and BNT162b2 from Pfizer-BioNTech, received Emergency Use Authorization (EUA) by the Food and Drug Administration (FDA) in December 2020 for persons ag...

Discussions